Royal London Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $69.7M | Sell |
551,867
-19,466
| -3% | -$2.56M | 0.13% | 146 |
|
|
2026
Q1 | $79.6M | Buy |
571,333
+19,196
| +3% | +$2.69M | 0.17% | 126 |
|
|
2025
Q4 | $67.8M | Sell |
552,137
-3,787
| -0.7% | -$460K | 0.14% | 138 |
|
|
2025
Q3 | $61.7M | Sell |
555,924
-15,294
| -3% | -$1.74M | 0.13% | 144 |
|
|
2025
Q2 | $63.3M | Sell |
571,218
-11,380
| -2% | -$1.21M | 0.14% | 139 |
|
|
2025
Q1 | $65.3M | Sell |
582,598
-124,167
| -18% | -$12.8M | 0.15% | 123 |
|
|
2024
Q4 | $65.3M | Sell |
706,765
-170,217
| -19% | -$15.3M | 0.16% | 114 |
|
|
2024
Q3 | $73.5M | Sell |
876,982
-22,527
| -3% | -$1.72M | 0.18% | 106 |
|
|
2024
Q2 | $61.7M | Sell |
899,509
-322,725
| -26% | -$21.5M | 0.16% | 112 |
|
|
2024
Q1 | $89.5M | Buy |
1,222,234
+177,359
| +17% | +$13.6M | 0.22% | 87 |
|
|
2023
Q4 | $84.6M | Buy |
1,044,875
+201,545
| +24% | +$15.7M | 0.24% | 84 |
|
|
2023
Q3 | $63.2M | Buy |
843,330
+223,694
| +36% | +$17.2M | 0.2% | 99 |
|
|
2023
Q2 | $47.7M | Buy |
619,636
+40,233
| +7% | +$3.21M | 0.15% | 119 |
|
|
2023
Q1 | $48.1M | Sell |
579,403
-51,328
| -8% | -$4.25M | 0.19% | 104 |
|
|
2022
Q4 | $54.1M | Buy |
630,731
+9,050
| +1% | +$717K | 0.24% | 84 |
|
|
2022
Q3 | $38.4M | Sell |
621,681
-32,231
| -5% | -$2.03M | 0.19% | 99 |
|
|
2022
Q2 | $40.4M | Sell |
653,912
-1,405
| -0.2% | -$87K | 0.19% | 107 |
|
|
2022
Q1 | $39M | Buy |
655,317
+25,011
| +4% | +$1.6M | 0.15% | 124 |
|
|
2021
Q4 | $45.8M | Sell |
630,306
-27,025
| -4% | -$1.86M | 0.17% | 111 |
|
|
2021
Q3 | $45.9M | Sell |
657,331
-17,327
| -3% | -$1.22M | 0.19% | 108 |
|
|
2021
Q2 | $46.4M | Sell |
674,658
-17,429
| -3% | -$1.16M | 0.19% | 109 |
|
|
2021
Q1 | $44.7M | Buy |
692,087
+21,515
| +3% | +$1.39M | 0.21% | 108 |
|
|
2020
Q4 | $39.1M | Buy |
670,572
+721
| +0.1% | +$43.5K | 0.21% | 106 |
|
|
2020
Q3 | $41.6M | Sell |
669,851
-1,819
| -0.3% | -$126K | 0.25% | 84 |
|
|
2020
Q2 | $50.1M | Sell |
671,670
-18,363
| -3% | -$1.41M | 0.35% | 67 |
|
|
2020
Q1 | $52.4M | Buy |
690,033
+3,417
| +0.5% | +$236K | 0.42% | 55 |
|
|
2019
Q4 | $44.6M | Buy |
686,616
+21,284
| +3% | +$1.39M | 0.31% | 79 |
|
|
2019
Q3 | $42.2M | Buy |
665,332
+2,211
| +0.3% | +$145K | 0.32% | 74 |
|
|
2019
Q2 | $44.8M | Sell |
663,121
-20,914
| -3% | -$1.38M | 0.42% | 56 |
|
|
2019
Q1 | $44.5M | Buy |
684,035
+13,325
| +2% | +$886K | 0.35% | 67 |
|
|
2018
Q4 | $41.5M | Buy |
670,710
+130,585
| +24% | +$9.13M | 0.36% | 63 |
|
|
2018
Q3 | $41.7M | Sell |
540,125
-12,323
| -2% | -$931K | 0.43% | 56 |
|
|
2018
Q2 | $39.1M | Buy |
+552,448
| New | +$39M | 0.39% | 58 |
|
|
2016
Q2 | $37.5M | Sell |
449,066
-30,392,585
| -99% | -$2.7B | 0.61% | 36 |
|
|
2016
Q1 | $336K | Buy |
30,841,651
+30,324,426
| +5,863% | +$2.73B | 0.48% | 40 |
|
|
2015
Q4 | $52.8M | Sell |
517,225
-3,211
| -0.6% | -$334K | 0.82% | 27 |
|
|
2015
Q3 | $51.1M | Buy |
+520,436
| New | +$57.8M | 0.82% | 27 |
|
|
2014
Q4 | $716K | Buy |
751,936
+75,720
| +11% | +$7.83M | 1.35% | 8 |
|
|
2014
Q3 | $72.7M | Buy |
676,216
+19,499
| +3% | +$1.91M | 1.83% | 4 |
|
|
2014
Q2 | $60.9M | Buy |
656,717
+230,912
| +54% | +$18M | 1.4% | 7 |
|
|
2014
Q1 | $34.2M | Buy |
425,805
+57,592
| +16% | +$4.52M | 0.8% | 23 |
|
|
2013
Q4 | $27.6M | Buy |
368,213
+3,960
| +1% | +$276K | 0.7% | 30 |
|
|
2013
Q3 | $25.4M | Buy |
364,253
+15,405
| +4% | +$921K | 0.68% | 31 |
|
|
2013
Q2 | $17.8M | Buy |
+348,848
| New | +$18.2M | 0.52% | 36 |
|
Other funds holding GILD
Royal London Asset Management's GILD Position: Q2 2026 in Review
Royal London Asset Management reduced its Gilead Sciences (GILD) stake by 3.4% in Q2 2026, selling an estimated $2.56M and leaving 551,867 shares worth $69.7M. The position accounts for 0.13% of the portfolio, ranked #146.
Royal London Asset Management first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $89.5M in Q1 2024. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Royal London Asset Management held 551,867 shares of Gilead Sciences worth $69.7M as of Q2 2026.
- Royal London Asset Management sold 19,466 Gilead Sciences shares in Q2 2026, an estimated $2.56M.
- Gilead Sciences made up 0.13% of Royal London Asset Management's portfolio in Q2 2026, its #146 holding.
- Royal London Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
- Royal London Asset Management's Gilead Sciences position peaked at $89.5M in Q1 2024.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.